Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -1091.82% is 239% below its 5-year average of -322.10%, near the high end of its 5-year range (-7136.00%–85.17%).
1.80% below its 12-month average of -1072.53%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1072.58%.
NET PROFIT MARGIN
-1091.82%
NET PROFIT MARGIN AVG TTM
-1072.53%
NET PROFIT MARGIN AVG 3Y
-417.40%
NET PROFIT MARGIN AVG 5Y
-322.10%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.80%
CURRENT VS 3Y AVG
-161.57%
CURRENT VS 5Y AVG
-238.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-419830.77%
vs the sector median at left
Opus Genetics, Inc.
Market Cap
$365.88M
Net Profit Margin
-1091.82%
TTM Avg
-1072.53%
3Y Avg
-417.40%
5Y Avg
-322.10%
Market Cap
$359.44M
Net Profit Margin
-5.49%
TTM Avg
-11.37%
3Y Avg
-410.78%
5Y Avg
-2049.25%
Market Cap
$356.90M
Net Profit Margin
0.00%
TTM Avg
-11651.99%
3Y Avg
-6142.69%
5Y Avg
-4693.07%
Market Cap
$357.08M
Net Profit Margin
-96.89%
TTM Avg
-148.47%
3Y Avg
-151.80%
5Y Avg
-119.69%
Market Cap
$356.88M
Net Profit Margin
-1786.27%
TTM Avg
-1435.22%
3Y Avg
-1851.09%
5Y Avg
-9692.20%
Market Cap
$356.54M
Net Profit Margin
4.81%
TTM Avg
5.28%
3Y Avg
5.16%
5Y Avg
8.74%
Market Cap
$376.48M
Net Profit Margin
-81.04%
TTM Avg
-157.37%
3Y Avg
-379.90%
5Y Avg
-317.33%
Market Cap
$377.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-102.82%
5Y Avg
-175.43%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $365.88M | -1091.82% | -1072.53% | -417.40% | -322.10% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.44M | -5.49% | -11.37% | -410.78% | -2049.25% |
| Embecta Corp. (EMBC)vs › | $357.44M | 8.59% | 7.90% | 10.47% | 19.48% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.90M | 0.00% | -11651.99% | -6142.69% | -4693.07% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.08M | -96.89% | -148.47% | -151.80% | -119.69% |
| Ocugen, Inc. (OCGN)vs › | $356.88M | -1786.27% | -1435.22% | -1851.09% | -9692.20% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.54M | 4.81% | 5.28% | 5.16% | 8.74% |
| Canopy Growth Corporation (CGC)vs › | $376.48M | -81.04% | -157.37% | -379.90% | -317.33% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.23M | 0.00% | 0.00% | -102.82% | -175.43% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $378.24M | -1392.61% | -834.59% | -416.33% | -277.55% |
Operating Margin
-271.9%
Net Profit Margin
-1091.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1072.58% |
| 2026-03-31 | -3038.25% |
| 2025-12-31 | -427.50% |
| 2025-09-30 | -566.87% |
| 2025-06-30 | -257.46% |
| 2025-03-31 | -187.51% |
| 2024-12-31 | -816.71% |
| 2024-09-30 | -194.62% |
| 2024-06-30 | -698.29% |
| 2024-03-31 | -415.31% |
| 2023-12-31 | -283.56% |
| 2023-09-30 | 46.59% |
| 2023-06-30 | -135.03% |
| 2023-03-31 | -331.10% |
| 2022-12-31 | 85.17% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | -865.03% |
| 2021-06-30 | -7136.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
